Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'

Schoffski, P.; Wozniak, A.; Kasper, B.; Aamdal, S.; Leahy, M.G.; Rutkowski, P.; ... ; Stacchiotti, S. (2018)

Article / Letter to editor

• alveolar soft part sarcoma
• ASPS
• transcription factor E3 (TFE3) gene rearrangement
• MET expression
• MET tyrosine kinase inhibitor
• crizotinib

• All authors: Schoffski, P.; Wozniak, A.; Kasper, B.; Aamdal, S.; Leahy, M.G.; Rutkowski, P.; Bauer, S.; Gelderblom, H.; Italiano, A.; Lindner, L.H.; Hennig, I.; Strauss, S.; Zakotnik, B.; Anthoney, A.; Albiges, L.; Blay, J.Y.; Reichardt, P.; Sufliarsky, J.; Graaf, W.T.A. van der; Debiec-Rychter, M.; Sciot, R.; Cann, T. van; Marreaud, S.; Raveloarivahy, T.; Collette, S.; Stacchiotti, S.
• Date: 2018-03-31
• Journal: Annals of Oncology
• Volume: 29
• Issue: 3
• Pages: 758 - 765
• DOI: doi:10.1093/annonc/mdx774